| 104.4347 0.135 (0.13%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 122.02 | 1-year : | 142.52 |
| Resists | First : | 104.47 | Second : | 122.02 |
| Pivot price | 101.33 |
|||
| Supports | First : | 100.17 | Second : | 97.51 |
| MAs | MA(5) : | 103.49 |
MA(20) : | 101.22 |
| MA(100) : | 93.36 |
MA(250) : | 0 | |
| MACD | MACD : | 1.5 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 94.8  |
D(3) : | 93.6 |
| RSI | RSI(14): 68.9 |
|||
| 52-week | High : | 104.47 | Low : | 77.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PPH ] has closed below upper band by 11.0%. Bollinger Bands are 23.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 104.52 - 104.83 | 104.83 - 105.18 |
| Low: | 102.98 - 103.37 | 103.37 - 103.8 |
| Close: | 103.76 - 104.34 | 104.34 - 104.99 |
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Wed, 24 Dec 2025
Why Are Investors Re-Evaluating Large Pharmaceutical Companies? - VanEck
Wed, 17 Dec 2025
Why PPH Keeps Working When Single Themes Break (NASDAQ:PPH) - Seeking Alpha
Thu, 27 Nov 2025
Should You Invest in the VanEck Pharmaceutical ETF (PPH)? - Yahoo Finance
Thu, 16 Oct 2025
Is VanEck Pharmaceutical (PPH) the Best Healthcare ETF to Buy? - Yahoo Finance
Mon, 06 Oct 2025
4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio - Zacks Investment Research
Fri, 03 Oct 2025
PPH: The Big Pharma ETF (NASDAQ:PPH) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|